ReWalk Robotics

LFWD

Market cap $12.6M

Positions Lifeward as a MedTech platform with a clear path to cashflow positive and long-term Biotech upside potential Up to $47 million strategic investment from Oramed and another investor is intended to provide Lifeward cash runway to profitability and diversify its portfolio across MedTech and BioTech Lifeward acquires Oramed's clinical-stage Protein Oral Delivery (POD™) technology adding exposure to a large, long-term Biotech market opportunity POD™ targets the $600+ billion injectable drugs market, including ORMD-0801, which has the potential to become the world's first commercialized oral insulin medicine MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd.

Transaction Will Transfer Oramed's Oral Drug Delivery Platform (POD™ Technology) to Lifeward and Positions Oramed as a Significant Shareholder Oramed will transfer POD™ platform to Lifeward while retaining management of clinical program Oramed will receive 49.9% beneficial ownership interest in Lifeward, a revenue-generating medical robotics company, including warrants Mark Grant, Lifeward CEO, with 25+ years experience in the diabetes sector at Medtronic and Bristol Myers Squibb, to lead combined platforms In addition, strategic investment by Oramed designed to bring Lifeward towards profitability Lifeward's FDA-approved ReWalk® and AlterG® products generated $26 million in last four quarters NEW YORK, Jan. 13, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) ("Oramed") and Lifeward Ltd. (NASDAQ: LFWD) ("Lifeward") today announced the signing of binding agreements for a strategic transaction between Oramed, Lifeward and a certain accredited investor.

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology designed to transform the lives of people with physical limitations or disabilities, announced today that its Board of Directors has appointed Bob Marshall as Chairman of the Board, effective January 1, 2026. He replaces Joseph Turk, who will transition off the Board in connection with his new position at Fresenius Medical Care.

Distribution agreement with Singapore-based Verita Neuro will provide patients the ReWalk Personal Exoskeleton as part of its multi-layered treatment modalities

Humana and UnitedHealthcare, which granted authorization in November, are the two largest Medicare Advantage providers in the U.S., accounting for  47% of all Medicare Advantage enrollees This latest approval will help enhance timely access to cutting-edge personal exoskeleton solutions for individuals with spinal cord injury Reimbursement coverage is expected to give Lifeward stronger revenue and cash flow dynamics to scale growth MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd.

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd.

Lifeward Ltd. ( LFWD ) Q3 2025 Earnings Call November 14, 2025 8:30 AM EST Company Participants Almog Adar - Chief Financial Officer William Grant - President, CEO & Director Conference Call Participants Yale Jen - Laidlaw & Company (UK) Ltd.

Record quarter of ReWalk systems placed for Medicare beneficiaries since fee schedule established  Ongoing efficiency initiatives drive 16% year-over-year decrease in quarterly cash burn and 27% decrease in quarterly Non-GAAP operating loss Entered into $3.0 million loan agreement with Oramed Ltd. providing additional capital support MARLBOROUGH, Mass.

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd.

LFWD secures CE mark for its ReWalk 7 Personal Exoskeleton, unlocking new European sales potential with advanced features.